The Many Names Of Acorda's MS Agent
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
"Late in the review process, it became clear that the established name 'fampridine' was very similar (especially in appearance when hand written) to the established name for 'famotidine,'" Division of Neurology Products Directors Russell Katz reported in a Jan. 18, 2010 memo. "Therefore, there was a risk for medication errors involving the two drugs."
You may also be interested in...
Everything Old Is New Again: History Of Compounding Shaped Ampyra REMS
Acorda’s Ampyra (dalfampridine) is a first-in-class new molecular entity in terms of FDA approval, but the drug substance’s history as a compounded drug raised the concerns necessitating a Risk Evaluation and Mitigation Strategy, FDA’s review documents show.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product